Baricitinib safety for events of special interest in populations at risk: analysis from randomised trial data across rheumatologic and dermatologic indications

Baricitinib safety for events of special interest in populations at risk: analysis from randomised trial data across rheumatologic and dermatologic indications

<strong>Introduction: </strong>Baricitinib, a Janus kinase (JAK) 1/2 inhibitor, is an approved treatment for rheumatoid arthritis (RA), atopic dermatitis (AD), and alopecia areata (AA). Further characterisation of adverse events of special interest (AESI) for JAK inhibitors in at-risk po...

Full description

Bibliographic Details
Main Authors: Taylor, PC, Bieber, T, Alten, R, Witte, T, Galloway, J, Deberdt, W, Issa, M, Haladyj, E, De La Torre, I, Grond, S, Wollenberg, A
Format: Journal article
Language:English
Published: Springer Nature 2023

Similar Items

Similar Items